Defendant
1 case as defendant.
Company overview. Incyte Corporation (NASDAQ: INCY) is a public biopharmaceutical company headquartered at 1801 Augustine Cut-Off, Wilmington, Delaware. It was founded April 1991 and is incorporated in Delaware; it is an S&P 500 component with no parent company. Recent company filings and market data put headcount at roughly 2,800 employees and annual revenue in the ~$5 billion range (FY2025).
Products / operations. Incyte discovers, develops and commercializes proprietary therapeutics across two franchises. Hematology/Oncology comprises JAKAFI (ruxolitinib), MONJUVI/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), ZYNYZ (retifanlimab) and NIKTIMVO (axatilimab). Inflammation and Autoimmunity is anchored by OPZELURA (ruxolitinib cream) for atopic dermatitis and vitiligo. Ruxolitinib is sold ex-U.S. by Novartis as JAKAVI. Historically, the company was a genomics/bioinformatics business — LifeSeq sequence databases and GEM microarrays, added via its January 1998 acquisition of Synteni — before refocusing on drug discovery and, later, exiting microarray manufacturing.
Patent-litigation posture. Operating company defending. In the tracked data Incyte appears once, as a defendant, with zero plaintiff-side cases — the profile of a commercial manufacturer of approved drugs, not a patent assertion entity. The single tracked matter is in the U.S. District Court for the Northern District of California.
Notable cases / context. Affymetrix, Inc. v. Hyseq, Inc. et al. (N.D. Cal., C 99-21163 / C 99-21164). Affymetrix's 1998 Delaware suits against Synteni, Inc. and Incyte Pharmaceuticals, Inc. over U.S. patents 5,445,934, 5,744,305 and 5,800,992 — covering high-density oligonucleotide arrays and two-color gene-expression monitoring — were transferred to N.D. Cal. and consolidated with the parallel Hyseq action. The court's 2001 claim-construction opinion (132 F. Supp. 2d 1212) construed the disputed array terms. The parties settled in December 2001; Affymetrix paid Incyte Genomics $4.5 million and the companies cross-licensed microarray and RNA-amplification patents. The matter reflects Incyte's 1990s microarray business rather than its current therapeutic portfolio.
Sources: Incyte 10-K/10-Q and investor releases; SEC Form 8-K (Sept. 1998); CourtListener/Justia, 132 F. Supp. 2d 1212; Forbes/MarketWatch company profiles.
Affymetrix brought an action against Hyseq and Incyte in the Northern District of California asserting Affymetrix's own array patents ('934, '305, '992, and '716). The 2001 decision at 132 F. Supp. 2d 1212 is a Markman claim-construction ruling and did not address US 6,018,041.